Clinical trials: Primary Insomnia
Primary Insomnia, Secondary Insomnia
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
- Trial name
- SLUMBER (NCT00784875)
- Testing
- LY2624803, zolpidem
- Where
- 49 sites in United States
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Insomnia, Suicidal Ideation
RCT of Brief CBT-I in Primary Care Veterans With Suicidal Thoughts
There is a strong association between insomnia and suicidal thoughts and behaviors. Insomnia also frequently co-occurs with other common conditions associated with suicide such as depression and posttraumatic stress disorder.
- Trial name
- NCT03603717
- Testing
- Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene
- Where
- 3 sites in United States
- Volunteers
- 283 people
- Sponsor
- VA Office of Research and Development
Insomnia, Primary
Study of Low Field Magnetic Stimulation (LFMS) on Measures of Sleep
Participants will be recruited and screened through ongoing studies in the sleep and anxiety disorders clinic. Participants with insomnia will be consented to complete several questionnaires, undergo a brief physical exam…
- Trial name
- NCT03050372
- Testing
- LFMS - Active
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Health Personnel, Stress
Cereset Research In Healthcare Workers During COVID-19
The purpose of this study is to evaluate the use of Cereset Research to improve the symptoms of stress in healthcare workers in an open label, waitlist controlled pilot clinical trial, during the period of COVID-19.
- Conditions
- Health Personnel, Stress, Anxiety, Insomnia
- Trial name
- NCT04682197
- Testing
- Cereset Research
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Insomnia
Digital Cognitive-Behavioral Therapy for Insomnia in Spanish Speaking Latinas/os (Dormir Mejor Study)
The primary objective of the proposed study is to examine the effectiveness of a culturally adapted digital program of cognitive behavioral therapy for insomnia (CBT-I) compared to minimally enhanced usual care (mEUC) on primary…
- Trial name
- NCT05353296
- Testing
- Digital cognitive behavioral therapy for insomnia (CBT-I) program, Minimally Enhanced Usual Care (mEUC), Somryst (culturally adapted)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Insomnia
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389).
- Trial name
- NCT00610675
- Testing
- Org 50081
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Sleep Initiation and Maintenance Disorders
Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia.
- Conditions
- Insomnia, Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias
- Trial name
- NCT00561821
- Testing
- Esmirtazapine
- Volunteers
- 538 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders, Mental Disorders
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
To investigate the long-term efficacy and safety of treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo, in participants with chronic primary insomnia.
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00631657
- Testing
- Esmirtazapine
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia Comorbid to Psychiatric Disorder, Primary Insomnia
Sequenced Therapies for Comorbid and Primary Insomnias
Chronic insomnia is a prevalent disorder associated with increased health care costs, impaired functioning, and an increased risk for developing serious psychiatric disorders.
- Trial name
- NCT01651442
- Testing
- Behavioral Insomnia Therapy, Zolpidem, Trazodone
- Where
- 2 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Jack Edinger, PhD
Insomnia, Primary Insomnia
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
The purpose of this study is to learn more about people with insomnia disorder and cognitive impairment. Cognitive impairment is difficulty with mental abilities such as thinking, knowing and remembering.
- Conditions
- Insomnia, Primary Insomnia, Chronic Insomnia
- Trial name
- NCT02290405
- Testing
- Multiple Sleep Latency Test (MSLT)
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Jack Edinger, PhD
Chronic Insomnia
Hyper-Arousal in Chronic Primary Insomnia
The purpose of this study is to determine whether individuals with chronic insomnia disorder have a higher degree of physiologic arousal (resulting in their trouble sleeping) than good sleepers.
- Trial name
- NCT02048878
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Primary Insomnia
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
- Trial name
- RESTORA 1 (NCT00608985)
- Testing
- almorexant, zolpidem
- Where
- 91 sites in Australia, Austria and 18 more
- Volunteers
- 709 people
- Sponsor
- Midnight Pharma, LLC
Sleep Disorder, Primary Insomnia
Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
SKP-1041 is a new formulation of a marketed sleeping agent called zaleplon. Zaleplon is currently available as Sonata as well as several generic formulations. Sonata and its generics induce sleep soon after ingestion.
- Trial name
- NCT00878553
- Testing
- SKP-1041 (experimental formulation of zaleplon)
- Volunteers
- 67 people
- Sponsor
- Somnus Therapeutics, Inc.
Obstructive Sleep Apnea of Adult, Insomnia
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study
Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS) was designed to develop and evaluate a new approach (patient-centered outcomes and coordinated-care management [PCCM]) for the…
- Conditions
- Obstructive Sleep Apnea of Adult, Insomnia, Circadian Rhythm Sleep Disorder, Sleep Related Movement Disorders
- Trial name
- SMART DOCS (NCT02037438)
- Testing
- CONV care for the diagnosis and treatment of sleep disorders, PCCM for the diagnosis and treatment of sleep disorders
- Where
- United States
- Volunteers
- 1,836 people
- Sponsor
- Stanford University
Chronic Primary Insomnia
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.
- Trial name
- NCT00606593
- Where
- 21 sites in United States
- Volunteers
- 112 people
- Sponsor
- Midnight Pharma, LLC